INT9586

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 1984
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 29
Total Number 29
Disease Relevance 6.79
Pain Relevance 11.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Eef1a2) GTPase activity (Eef1a2) cytoplasm (Eef1a2)
Anatomy Link Frequency
spinal cord 3
DGC 2
spinal cord neurons 2
brain 1
bladder 1
Eef1a2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Spinal cord 305 100.00 Very High Very High Very High
Calcitonin gene-related peptide 231 100.00 Very High Very High Very High
primary somatosensory cortex 211 100.00 Very High Very High Very High
Dorsal horn 163 100.00 Very High Very High Very High
Inflammation 97 99.96 Very High Very High Very High
Hippocampus 254 99.92 Very High Very High Very High
Nerve growth factor 557 99.80 Very High Very High Very High
Dynorphin 24 99.60 Very High Very High Very High
Enkephalin 22 99.44 Very High Very High Very High
fluoxetine 3 99.12 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 111 99.96 Very High Very High Very High
Overactive Bladder 317 99.44 Very High Very High Very High
Aids-related Complex 155 99.28 Very High Very High Very High
Adhesions 11 98.68 Very High Very High Very High
Heart Arrhythmia 287 97.16 Very High Very High Very High
Urological Neuroanatomy 93 96.56 Very High Very High Very High
Cystitis 40 96.52 Very High Very High Very High
Ganglion Cysts 14 93.40 High High
Hypertension 97 89.16 High High
Cardiovascular Disease 77 88.40 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Statins have been proven to be potent anti-inflammatory agents.8–10
Gene_expression (anti) of Statins associated with inflammation
1) Confidence 0.65 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2704895 Disease Relevance 2.33 Pain Relevance 0.39
We used multivariable logistic regression analyses to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for statin use compared with no use, and joint use of statin and NSAIDs compared with use of neither.
Gene_expression (use) of statin in joint
2) Confidence 0.44 Published 2010 Journal Pharmacoepidemiol Drug Saf Section Body Doc Link 20582910 Disease Relevance 0 Pain Relevance 0
CONCLUSION: The present results do not support a protective effect of statin use, or statin and NSAID use, on the risk of advanced prostate cancer.


Gene_expression (use) of statin
3) Confidence 0.44 Published 2010 Journal Pharmacoepidemiol Drug Saf Section Body Doc Link 20582910 Disease Relevance 0 Pain Relevance 0
The results of these studies indicate that ENK and DYN immunoreactivities coexist in most, but not all, neurons in the DGC of L6 and S1 and that a difference exists between L6 and S1 in the extent of coexistence of these peptides.
Gene_expression (coexist) of S1 in DGC associated with dynorphin and enkephalin
4) Confidence 0.39 Published 1986 Journal Brain Res. Section Abstract Doc Link 2875766 Disease Relevance 0 Pain Relevance 1.41
The results of these studies indicate that ENK and DYN immunoreactivities coexist in most, but not all, neurons in the DGC of L6 and S1 and that a difference exists between L6 and S1 in the extent of coexistence of these peptides.
Gene_expression (exists) of S1 in DGC associated with dynorphin and enkephalin
5) Confidence 0.39 Published 1986 Journal Brain Res. Section Abstract Doc Link 2875766 Disease Relevance 0 Pain Relevance 1.36
S1 was continuously present during half of the sessions, and S2 was continuously present during the remaining sessions.
Gene_expression (present) of S1
6) Confidence 0.31 Published 1984 Journal Psychopharmacology (Berl.) Section Abstract Doc Link 6425896 Disease Relevance 0 Pain Relevance 0.09
We have explored the effects of long-term fluoxetine administration of G alpha s, G alpha i1, G alpha i2, G alpha o, G alpha q and G alpha 12 mRNA expression in various rat brain regions using reverse transcriptase-polymerase chain reaction (RT-PCR)-mediated cross-species partial cDNA cloning.
Gene_expression (expression) of alpha i2 in brain associated with fluoxetine
7) Confidence 0.29 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1426031 Disease Relevance 0.07 Pain Relevance 0.33
In control Wistar rats, PACAP immunoreactivity was expressed in fibers in the superficial dorsal horn at all segmental levels examined (L1, L2, and L4-S1).
Gene_expression (expressed) of S1 in dorsal horn associated with dorsal horn
8) Confidence 0.18 Published 2000 Journal J. Comp. Neurol. Section Abstract Doc Link 10754506 Disease Relevance 0.43 Pain Relevance 0.05
For example, the proportion of patients adherent with statin therapy at 6 months after initiating therapy in this study was 44% in the statin add-on cohort, comparable with the proportion of patients adherent with statin therapy in our previous analysis (43%);21 in contrast, the proportion adherent with statin therapy in the single-pill cohort was 51%, which approaches the proportion adherent with antihypertensives in our earlier investigation (58%).21
Gene_expression (therapy) of statin
9) Confidence 0.10 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778419 Disease Relevance 0 Pain Relevance 0
For example, the proportion of patients adherent with statin therapy at 6 months after initiating therapy in this study was 44% in the statin add-on cohort, comparable with the proportion of patients adherent with statin therapy in our previous analysis (43%);21 in contrast, the proportion adherent with statin therapy in the single-pill cohort was 51%, which approaches the proportion adherent with antihypertensives in our earlier investigation (58%).21
Gene_expression (therapy) of statin
10) Confidence 0.10 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778419 Disease Relevance 0 Pain Relevance 0
For example, the proportion of patients adherent with statin therapy at 6 months after initiating therapy in this study was 44% in the statin add-on cohort, comparable with the proportion of patients adherent with statin therapy in our previous analysis (43%);21 in contrast, the proportion adherent with statin therapy in the single-pill cohort was 51%, which approaches the proportion adherent with antihypertensives in our earlier investigation (58%).21
Gene_expression (therapy) of statin
11) Confidence 0.10 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778419 Disease Relevance 0 Pain Relevance 0
18 years) who filled a new prescription for either single-pill amlodipine/atorvastatin or a statin during a 36-month period (July 1, 2004 to June 30, 2007); the prescription fill date of the initial amlodipine/atorvastatin or statin prescription was considered the index date.
Gene_expression (prescription) of statin
12) Confidence 0.10 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778419 Disease Relevance 0.07 Pain Relevance 0
Overall statin and amlodipine exposure
Gene_expression (Overall) of statin
13) Confidence 0.09 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778419 Disease Relevance 0.06 Pain Relevance 0
Patients were excluded who had: a single-pill amlodipine/atorvastatin or statin prescription during the 360 days prior to the index date; no evidence of amlodipine use from 360 days pre-index date through 30 days post-index date; an amlodipine prescription on the same day as the single-pill amlodipine/atorvastatin prescription; or no evidence of a diagnosis of hypertension pre-index through the index date.
Gene_expression (prescription) of statin associated with hypertension
14) Confidence 0.09 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778419 Disease Relevance 0.09 Pain Relevance 0
In multivariable logistic regression modeling, patients who switched to amlodipine/atorvastatin had 1.64-times greater odds of achieving adherence with their statin therapy than those receiving a statin as add-on therapy (P < 0.001; Figure 1), after adjusting for pre-index adherence (PDC ?
Gene_expression (therapy) of statin
15) Confidence 0.09 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778419 Disease Relevance 0.21 Pain Relevance 0.06
Increased expression of CGRP-IR in lumbosacral spinal cord (L6-S1) in NGF-treated rats compared to saline treated rats
Gene_expression (expression) of S1 in spinal cord associated with nerve growth factor, spinal cord and calcitonin gene-related peptide
16) Confidence 0.06 Published 2007 Journal BMC Physiol Section Body Doc Link PMC2000875 Disease Relevance 0.37 Pain Relevance 1.02
In contrast, normalized IEG expression in S1 did not differ significantly between pre-experience WK and post-experience SWS or IS.
Gene_expression (expression) of S1 associated with primary somatosensory cortex
17) Confidence 0.05 Published 2007 Journal Frontiers in Neuroscience Section Body Doc Link PMC2577304 Disease Relevance 0.28 Pain Relevance 0.69
Despite the link between cortical IEG upregulation and post-experience REM sleep, analysis of the relation between IEG expression in S1 and time spent in REM sleep within 60?
Gene_expression (expression) of S1 associated with primary somatosensory cortex
18) Confidence 0.05 Published 2007 Journal Frontiers in Neuroscience Section Body Doc Link PMC2577304 Disease Relevance 0.23 Pain Relevance 0.60
The following regions were analyzed in the L5-S1 spinal cord from both NGF and saline animals: LDH(laminae I and II), MDH, DCM, the region of the SPN (L6-S1), LCP (L6-S1).
Gene_expression (spinal cord) of S1 in spinal cord associated with nerve growth factor, dorsal horn, urological neuroanatomy and spinal cord
19) Confidence 0.05 Published 2007 Journal BMC Physiol Section Body Doc Link PMC2000875 Disease Relevance 0.10 Pain Relevance 0.64
In NGF-treated rats undergoing conscious cystometry, significant increases in CGRP-IR in L6-S1 spinal cord regions known to participate in micturition reflexes were observed (Fig. 7).
Gene_expression (regions) of S1 in spinal cord associated with nerve growth factor, overactive bladder, spinal cord and calcitonin gene-related peptide
20) Confidence 0.05 Published 2007 Journal BMC Physiol Section Body Doc Link PMC2000875 Disease Relevance 0.47 Pain Relevance 1.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox